Related Experiment Video
Updated: Jun 7, 2025

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Cardiovascular disease development in COVID-19 patients admitted to a tertiary medical centre in Iran
Erfan Kazemi1, Salman Daliri2, Reza Chaman3
1Medical student, Student Research Committee.
Insights
COVID-19 patients frequently experience cardiovascular diseases (CVDs), including chest pain and new-onset hypertension. This study highlights the high incidence of cardiac complications in individuals with coronavirus disease 2019.
Area of Science:
- Cardiology
- Infectious Diseases
- Internal Medicine
Background:
- Cardiovascular diseases (CVDs) are a significant concern in patients with coronavirus disease 2019 (COVID-19).
- Understanding the spectrum of CVDs in COVID-19 is crucial for patient management.
Purpose of the Study:
- To investigate the occurrence of symptomatic and asymptomatic cardiovascular diseases in COVID-19 patients.
- To document the types and incidence of cardiac manifestations in a cohort of COVID-19 patients.
Main Methods:
- A cross-sectional study included 690 COVID-19 patients.
- Cardiovascular consultation, ECG, 2D transthoracic echocardiography (TTE), and serum biomarkers (CPK-MB, cTn) were performed.
- Documented CVD manifestations included chest pain, abnormal markers, angina, myocardial infarction (MI), myocarditis, and hypertension.
Main Results:
- The most common symptom was chest pain (46%). New-onset hypertension occurred in 10% of patients.
- Myocarditis (1.7%), myocardial infarction (0.7%), and unstable angina (2.8%) were diagnosed.
- Pericardial effusion was found in 31.1% on TTE, and abnormal ECG findings (T-wave changes) were common (41.8%).
Conclusions:
- Cardiovascular involvement is prevalent in COVID-19 patients.
- A significant proportion of COVID-19 patients exhibit cardiac complications requiring attention.
Abstract:
Cardiovascular diseases (CVDs) have been reported to occur in a significant number of patients diagnosed with coronavirus disease 2019 (COVID-19). We report our experience regarding the occurrence of symptomatic and asymptomatic CVDs in COVID-19 patients. In this cross-sectional study, 690 COVID-19 patients were included. Cardiovascular consultation had been requested for all of the patients based on their primary clinical examination, vital signs, and electrocardiogram (ECG). Additionally, 2D transthoracic echocardiography (TTE), and myocardial injury serum biomarkers assays (creatine phosphokinase-MB [CPK-MB] and cardiac troponins [cTn]) were measured once. Manifestations of CVDs, such as chest pain, abnormal serum markers, unstable angina, myocardial infarction (MI), myocarditis, and new-onset hypertension, were documented. The most common symptom was left hemithorax and interscapular pain (317 patients, 46%). New-onset high systolic and diastolic blood pressures were seen in 67 patients (10%). Unstable angina, MI, and myocarditis were, respectively, diagnosed in 20 (2.8%), five (0.7%), and 12 (1.7%) patients. On TTE, pericardial effusion was diagnosed in 139 patients (31.1%). The most common abnormal ECG changes seen were regarding the T-wave, including flat T-wave (148 cases, 21.4%) and inverted T-wave (141 cases, 20.4%). Serum cTn levels were positive or weekly positive in 17 cases (7.4%). The incidence rate of cardiovascular involvements was high in COVID-19 patients.
More Related Videos
Related Concept Videos
Myocarditis III: Medical Management
Rheumatic Heart Disease III: Medical Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Endocarditis III: Medical Management
Rheumatic Heart Disease I: Introduction
Endocarditis II: Clinical features and Diagnostic Tests

